



Pathological Features and Genetic Research on Gastrointestinal Cancer

Guest Editors:

Dr. Hsiangyao Shih

Department of Anatomy, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan

Dr. Lin Han Chen

Department of Anatomy, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan

Deadline for manuscript submissions:

closed (15 November 2023)

Message from the Guest Editors

Gastrointestinal (GI) cancers account for around a quarter of global cancer incidence and one-third of all cancer-related deaths. Although the recent progress in therapeutic and disease mechanisms has been uncovered, the mortality and societal impact of GI cancer is experienced worldwide. It is still one of the critical challenges of public health. Recently, new therapies within newly discovered molecular biology have been reported and successfully decreased the mortality of GI cancer, such as targeted therapy, immunotherapy, nanomedicine, and CRISPR/Cas9 therapeutics. To develop and translate these therapeutic methods into the clinic, the understanding of precise pathological features and genetic information is urgently needed.

Therefore, in the proposed Special Issue of *Biomedicines*, we want to recruit works covering therapies related to the latest molecular tools for GI cancer. We also welcome the submission of papers covering findings related to molecular biomarker and pathological features, which can help with the early diagnosis and prevention of GI cancer.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI